| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 1.5 | 2.8 | 1.5 |
| Other income | 6.8 | 2.8 | 1.2 |
| Total income | 8.3 | 5.6 | 2.7 |
| Profit before exceptional items & tax | -45.6 | -101.9 | -43.9 |
| Profit before tax | -45.6 | -101.9 | -43.9 |
| Net profit | -45.6 | -101.9 | -43.9 |
| Operating margin | -549.4% | n/m | n/m |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | +0.00% |
|---|
NSE results filing, NSE: SUVEN. Figures extracted from the filing.
Suven Life Sciences Ltd: key numbers
- Share price
- ₹307.00
- Market cap
- ₹8,675 Cr
- Revenue (annual)
- ₹7.11 Cr
- Net profit (annual)
- ₹-276.3 Cr
- P/E (TTM)
- -24.6×Sector 53.1×
- Promoter holding
- 65.47%-4.68% QoQ
- FII holding
- 0.48%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Suven Life Sciences Ltd
All →Suven Life Sciences Business Update
Suven Life Sciences has completed patient enrollment for its global Phase-3 clinical study of Masupirdine. A total of 424 patients were randomized across the USA and Europe.
- clinical trial enrollment
- 424.0 patients
Suven Life Sciences Annual General Meeting
Suven Life Sciences held its 37th Annual General Meeting on August 25, 2026. The company submitted the proceedings, scrutineer's report, and voting results.
Suven Life Sciences Other Announcement
Suven Life Sciences Limited submitted its Monitoring Agency Report for the quarter ended June 30, 2026. The report confirms the utilization of Rs. 857.64 Crore raised via preferential issue.
- Value
- ₹857.6 Cr
Suven Life Sciences Q1 FY27 Results: Net Loss of ₹127.6 Cr, Loss Widens
Suven Life Sciences Ltd reported revenue from operations of ₹3.6 Cr (+89.5% YoY) and a net loss of ₹127.6 Cr for Q1 FY27.
- Key figure
- Net loss ₹127.6 Cr
Suven Life Sciences Board Meeting Date
Suven Life Sciences will hold a board meeting on August 6, 2026, to consider and approve its unaudited financial results for the quarter ending June 30, 2026.
Suven Life Sciences Annual General Meeting
Suven Life Sciences has issued a notice for its 37th Annual General Meeting on August 25, 2026. The agenda includes adopting financial statements and approving a related party transaction.
- Value
- ₹3.84 Cr